Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silmitasertib + Chemotherapy in Relapsed/Refractory Solid Tumors
NCT06541262Phase 2Recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Oct 2024
- Primary completion
- Nov 2030
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of silmitasertib in neuroblastoma, Ewing sarcoma, osteosarcoma (OS) and 2 more (4 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Adverse Events, Dose Limiting Toxicities at 21 days and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
silmitasertib
03
Conditions
neuroblastomaEwing sarcomaosteosarcoma (OS)rhabdomyosarcoma (RMS)Liposarcoma
Beyond the preview
Go deeper on NCT06541262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541262.